Study Details | To Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Mezagitamab (TAK-079) in Patients With Primary IgA Nephropathy in Combination With Stable Background Therapy |
Protocol Number | TAK-079 |
Phase | Ib |
Therapeutic Area | Nephrology |
Subject Types | With Medical Condition |
Indication | Primary IgA Nephropathy |
Principal Investigator | A/Prof Jimmy Teo Boon Wee |
Investigator Product / Device | Mezagitamab (TAK-079) |
Sponsor | Takeda Development Center Americas, Inc |